ZA200103946B - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.

Info

Publication number
ZA200103946B
ZA200103946B ZA200103946A ZA200103946A ZA200103946B ZA 200103946 B ZA200103946 B ZA 200103946B ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 A ZA200103946 A ZA 200103946A ZA 200103946 B ZA200103946 B ZA 200103946B
Authority
ZA
South Africa
Prior art keywords
meta
particles
producing particles
amorphous
crystalline
Prior art date
Application number
ZA200103946A
Other languages
English (en)
Inventor
Mikael Bisrat
Saeed Moshashaee
Haakan Nyqvist
Mustafa Demirbueker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200103946B publication Critical patent/ZA200103946B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Recrystallisation Techniques (AREA)
  • Saccharide Compounds (AREA)
ZA200103946A 1998-11-23 2001-05-15 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state. ZA200103946B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Publications (1)

Publication Number Publication Date
ZA200103946B true ZA200103946B (en) 2002-10-30

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200103946A ZA200103946B (en) 1998-11-23 2001-05-15 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.

Country Status (27)

Country Link
US (1) US6475524B1 (cs)
EP (1) EP1133285B1 (cs)
JP (1) JP4447169B2 (cs)
KR (1) KR100697780B1 (cs)
CN (1) CN1198592C (cs)
AT (1) ATE318583T1 (cs)
AU (1) AU767313B2 (cs)
BR (1) BR9915592A (cs)
CA (1) CA2349633C (cs)
CY (1) CY1105609T1 (cs)
CZ (1) CZ20011778A3 (cs)
DE (1) DE69930158T2 (cs)
DK (1) DK1133285T3 (cs)
EE (1) EE200100275A (cs)
ES (1) ES2258865T3 (cs)
HU (1) HUP0104182A2 (cs)
IL (2) IL143040A0 (cs)
IS (1) IS5946A (cs)
NO (1) NO20012514L (cs)
NZ (1) NZ511494A (cs)
PL (1) PL348523A1 (cs)
PT (1) PT1133285E (cs)
SE (1) SE9804000D0 (cs)
SK (1) SK7032001A3 (cs)
TR (1) TR200101424T2 (cs)
WO (1) WO2000030614A1 (cs)
ZA (1) ZA200103946B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
CA2433169A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Porous substances and methods for producing the same
WO2003004142A1 (en) * 2001-07-02 2003-01-16 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007520509A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105065A2 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
US8585943B2 (en) * 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
EP2453894B1 (en) 2009-07-15 2015-11-04 Theravance Biopharma R&D IP, LLC Crystalline freebase form of a biphenyl compound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
BR112013004698B1 (pt) 2010-08-27 2022-03-22 Neonc Technologies Inc. Composições farmacêuticas compreendendo derivados de poh
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
JP6560986B2 (ja) 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
EP4389765A2 (en) 2018-02-08 2024-06-26 University of Southern California Methods of permeabilizing the blood brain barrier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
ATE212545T1 (de) * 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
CN100548277C (zh) 1997-03-20 2009-10-14 先灵公司 粉末附聚物的制备方法

Also Published As

Publication number Publication date
CN1198592C (zh) 2005-04-27
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
DK1133285T3 (da) 2006-06-06
IL143040A0 (en) 2002-04-21
SE9804000D0 (sv) 1998-11-23
AU767313B2 (en) 2003-11-06
BR9915592A (pt) 2001-08-07
WO2000030614A1 (en) 2000-06-02
DE69930158T2 (de) 2006-11-16
CA2349633A1 (en) 2000-06-02
NO20012514L (no) 2001-07-19
ES2258865T3 (es) 2006-09-01
SK7032001A3 (en) 2001-11-06
CA2349633C (en) 2009-06-02
TR200101424T2 (tr) 2001-12-21
CZ20011778A3 (cs) 2001-08-15
DE69930158D1 (de) 2006-04-27
JP2002530319A (ja) 2002-09-17
IL143040A (en) 2009-09-01
IS5946A (is) 2001-05-18
EP1133285A1 (en) 2001-09-19
EE200100275A (et) 2002-10-15
PL348523A1 (en) 2002-06-03
US6475524B1 (en) 2002-11-05
EP1133285B1 (en) 2006-03-01
AU2010400A (en) 2000-06-13
KR100697780B1 (ko) 2007-03-21
NO20012514D0 (no) 2001-05-22
CY1105609T1 (el) 2010-07-28
JP4447169B2 (ja) 2010-04-07
HUP0104182A2 (hu) 2002-03-28
NZ511494A (en) 2003-11-28
KR20010080534A (ko) 2001-08-22
PT1133285E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
ZA200103946B (en) A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state.
NZ514574A (en) Novel method of treatment
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001041761A3 (en) Valdecoxib compositions
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
WO1996015786A3 (en) Oral compositions containing ondansetron
BG104476A (en) Therapeutical form for tolterodin with controlled release
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
CA2330480A1 (en) Controlled release formulation of divalproex sodium
CA2198706A1 (en) Methods for the treatment of inflammatory joint disease
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
CA2501738A1 (en) Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
ZA906057B (en) 4-(n-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
WO2001042272A3 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
CA2279943A1 (en) Treatment of skin disorders
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO1999021005A3 (en) Pharmaceutical grade st. john's wort